To study the efficacy of CDK4/6 inhibitor against human GBM, actions of palbociclib and ribociclib we firstly examined with five human GBM cell lines: NZ308, U87MG, LN229, SF763, and U251. This evidence concerns the gene CDK4 and glioblastoma.